Altimmune Inc

ALTNASDAQ · USD
3.24USD0.00 (0.00%)
159

Altimmune Inc (ALT) Covered Calls

As of September 16, 2026, ALT has 25 covered call opportunities in the coming three months. Return ranges from 11.5 to 215.8% until expiration. Annualized return ranges from 11.5 to 358.5%. The nearest expiration is October 16, 2026. Maximum potential profit is $697.

Read more

Running ALT covered calls helps you generate consistent income from Altimmune Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Altimmune Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ALT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ALT stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ALT covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Altimmune Inc covered call is worth writing.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc.

in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Income-focused investors, long-term ALT holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ALT covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Altimmune Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile60.71% Neutral
  • Market cap (M$)630
  • 52 weeks high-49.69%
  • 52 weeks low26.56%
  • Analyst recommendationStrong Buy
    1.33
  • Target price$17.12
    428.40% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-05
  • P/E
  • Future P/E
  • EPS (ttm)-0.79
  • EPS growth next 5 years14.12%

As of September 16, 2026

2027-01-151227.00116.720.100.25387.00119.81358.46-3.10+0.206,6840.15
2027-01-151226.0085.760.100.50287.0088.85265.84-3.10+0.292570.40
2026-12-18945.0054.800.100.30187.0057.89224.80-3.10+0.261,3560.20
2027-01-151225.0054.800.200.30197.0060.99182.47-6.19+0.3012,3200.10
2027-03-191856.0085.760.150.55292.0090.40178.36-4.64+0.321220.40
2026-12-18944.5039.320.150.50142.0043.96170.71-4.64+0.36340.35
2028-01-2149310.00209.600.200.55697.00215.79159.76-6.19+0.298,7250.35
2027-03-191855.5070.280.050.75232.0071.83141.71-1.55+0.3690.70
2027-01-151224.5039.320.200.30147.0045.51136.16-6.19+0.323840.10
2026-10-16313.508.360.100.2037.0011.46134.87-3.10+0.386700.10

As of September 16, 2026

Sell covered calls with the data behind you

Find the best ALT covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial